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Summary A series of 24 paired samples of colorectal carcinoma and the respective normal colorectal mucosa
were analysed for Epidermal Growth Factor Receptor (EGFR) content by means of a standardised ligand
binding assay.
We, for the first time, found that EGFR levels are statistically significantly higher in normal colorectal
mucosa biopsy samples than they are in colorectal carcinoma biopsy samples, the median EGFR levels being
77.5fmolmg-' of membrane protein (range 35-239), against 46fmolmg-' of membrane protein (range
22-81), respectively, P<0.001. In addition, we found that there are significant regional differences in EGFR
expression in the normal human colon mucosa. The EGFR levels were significantly higher in samples from the
proximal part of the colon than they were in samples from the distal part, the median EGFR levels being
124fmolmg-' of membrane protein (range 70-239) vs 55fmolmg-' membrane protein (range 35-156),
P<0.05. The EGFR levels of the colorectal carcinoma samples did not show any regional variation.
The Epidermal Growth Factor (EGF) and its receptor
(EGFR) have been implicated in the process of malignant
transformation of cells (Sporn & Todaro, 1980; Sporn &
Roberts, 1985). Both the Transforming Growth Factor a
(TGFax), an EGF-related protein (Hanauske et al., 1987;
Coffey et al., 1987; Anzano et al., 1989), and the EGFR
(Bradly et al., 1986; Murthy et al., 1989), have been shown to
be expressed in vitro by human colon carcinoma derived cell
lines.
Only a few studies on the appearance of EGFR in human
colorectal cancer have been published (Yasui et al., 1988;
Ravikumar et al., 1989; Magnusson et al., 1989; Rothbauer
et al., 1989; Moorghen et al., 1990; Steele et al., 1990a; Steele
et al., 1990b; Koretz et al., 1990). Research groups using
immunohistochemical methods to detect EGFR in colorectal
tissue, reported that EGFR was not detectable at all (Ravi-
kumar et al., 1989), or detectable in only a limited number of
normal or malignant biopsy samples (Yasui et al., 1988;
Moorghen et al., 1990; Steele et al., 1990a; Steele et al.,
1990b; Koretz et al., 1990). In contrast, groups using ligand
binding assays reported EGFR expression in all cases of
normal and malignant colorectal tissue, the EGFR levels
being the same in normal and carcinomatous colorectal tissue
(Yasui et al., 1988; Rothbauer et al., 1989; Moorghen et al.,
1990). In addition, one study, also using a ligand binding
assay, analysing only colorectal carcinomas, detected EGFR
in only 25% ofthe tumour samples (Magnusson et al., 1989).
Encouraged by these conflicting data, we decided to re-eval-
uate the EGFR expression in colorectal tissue using a
standardised, multiple point, ligand binding assay, quality
controlled by the European Organization for Research and
Treatment of Cancer (Benraad & Foekens, 1990).
Patients and methods
Colorectal tissue biopsy samples from 24 patients (14 males
and ten females, median age 62 and 72 years, respectively)
with, non-familiar, adenomatous, colorectal cancer were
excised by the pathologist within 1 h after surgical resection
(resections performed between October 1989 and October
1990). From each patient, a specimen from the tumour as
well as from the adjacent (approximately 10 cm distant from
the tumour), non-malignant colorectal tissue were obtained.
Adjacent tissue sections of both, colorectal carcinomas and
normal colorectal tissues were histologically verified. Tissue
samples were immediately frozen in liquid nitrogen and sub-
sequently stored at -80°C.
After thawing, the normal colorectal tissue samples were
spread on an ice-cooled glass plate The mucosa was speci-
fically harvested by carefully scraping the tissue sample sur-
face with a scalpel until a smooth surface, indicative of the
muscularis mucosae, was obtained. Colorectal carcinoma
samples were carefully freed from necrotic debris and con-
tiguous tissues prior to homogenisation.
Mucosal scraping (0.5-1.5 g) and carcinoma tissue samples
(0.6-3 g) were homogenised in a motor driven glass-teflon
homogeniser (five strokes at 1,000 r.p.m.) in a buffer (0.02 M
Tris/HCl, pH 7.4, containing 1.4 mM dithiothreitol and 0.25 M
sucrose). The homogenates were centrifuged for 10min at
10,000 g, 4°C, to spin down nuclei and other coarse cell
fragments. The supernatants were recentrifuged for 25 min at
12,000g, 4°C. The cell membrane pellets thus obtained were
resuspended in EGFR assay buffer (0.02 M phosphate buffer,
pH 7.4, containing 0.15 M NaCl and 70 fig ml- Bacitracin)
by means of ultrasound bursts (MSE Soniprep-150: nominal
frequency 23 kHz, amplitude 10 tm) for 10 sec, on ice. Final
cell membrane protein concentration 0.5mgml-1 (Lowry
method using Bovine Serum Albumin as a standard) (Lowry
et al., 1951). EGFR assays were performed in a manner
similar to that described previously (Benraad & Foekens,
1990; Koenders et al., 1991). To summarise: eight 100fil
aliquots of cell membrane preparation were incubated with
'251-mouse-EGF ('25I-mEGF) tracer at concentrations ranging
from 0.15 to 3.5 nM. Aspecific binding was assessed in dupli-
cate using 1 nM 1251-mEGF and a 250-fold excess of unlabell-
ed mEGF. Receptor-bound and free ligand were separated
using hydroxylapatite. Receptor values were calculated by
Scatchard analysis and expressed in fmol mg-' of membrane
protein (Scatchard, 1949). The cut-off level used for the
EGFR-assay is 6 fmol mg-' of membrane protein. The
tumours' Dukes stage was classified according to the criteria
provided by Astler and Coller (1954).
Associations between variables were assessed by the Spear-
man rank correlation test (the correlation coefficient denoted
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as r, and the significance level as Ps). Homogeneity between
groups was tested nonparametrically by means of the Wil-
coxon two-sample test (Chi2 denoted as X2w, degrees of free-
dom as d.f. and the level of significance as P). Differences
between paired observations were tested by means of a two-
sided t-test (Students'-t denoted as t and level of significance
as P,-,1,t). All calculations were performed using SAS (Statis-
tical Analysing System) statistical software (SAS Institute
Inc., 1982).
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Results
Eleven of our patients had their tumours located in the
proximal part of the colon (caecum, ascending, transverse
and descending) and 13 in the distal part (sigmoid and
rectum). Six patients had tumours with a Dukes stage B, 14
with a stage C and four with a stage D. The majority of the
tumours (n = 14) were of intermediate histological grade
(grade 2), two tumours were well differentiated (grade 1) and
eight were poorly differentiated tumours (grade 3) (Table I).
Plasma membrane enriched fractions of both colorectal
carcinoma and normal colorectal mucosa biopsy samples
were all (n = 48) found to contain EGFR (Table I). For the
normal colorectal mucosa biopsy samples, the EGFR levels
were significantly higher in samples from the proximal part
of the colon than in samples from the distal part of the
colon, the median EGFR levels being 124 fmol mg-' of
membrane protein (range 70-239) and 55 fmol mg-' of
membrane protein (range 35-156) X2w= 4, d.f. = 1, Pw=
0.02) (Figure la).
Carcinoma biopsy samples were shown to contain similar
or decreased EGFR levels in 22/24 (92%) cases as compared
with the respective normal mucosa samples, whereas in two
rectal carcinomas, the EGFR levels were moderately higher.
The EGFR levels in the normal colorectal mucosa biopsy
samples (median EGFR level 77.5 fmol mg-' of membrane
protein (range 35-239)) were significantly higher than the
levels in the carcinoma biopsy samples (46 fmol mg ' of
membrane protein (range 22-81)), irrespective of their intra-
colic localisation (data not shown), both when analysed as
paired observations (t = 4.4, d.f. = 1, P,-,eS = 0.001), as well
Table I Patient and tumour characteristics
EGFR
No.Age Sex Localisation Stage Grade Mucosa Carcinoma
1 71 M Descending colon D 3 239 45
2 55 M Sigmoid C 3 47 24
3 69 M Rectum B 2 80 49
4 78 M Ascending colon C 2 70 22
5 54 F Rectum C 2 75 65
6 79 F Transverse colon C 2 80 58
7 73 F Sigmoid B 2 62 34
8 64 M Rectum C 3 53 37
9 84 F Caecum B 1 152 24
10 57 F Transverse colon B 2 156 23
11 86 F Ascending colon D 3 88 81
12 86 F Rectum C 2 55 45
13 59 M Caecum D 2 84 53
14 63 F Transverse colon C 2 134 34
15 71 F Rectum C 2 35 47
16 69 F Sigmoid C 2 71 32
17 53 M Rectum C 2 46 52
18 46 M Rectum C 3 46 31
19 60 M Rectum C 3 53 22
20 69 M Ascending colon C 2 124 64
21 57 M Rectum B 2 70 69
22 70 M Ascending colon B 3 91 77
23 59 M Caecum D 3 154 72
24 65 M Rectum B 1 156 49
Age: patient age in years; Sex: male, female patients; Stage: tumour
stage according to Dukes. Grade: Histological tumour grade, 1 = well,
2 = moderately and 3 = poorly differentiated tumours. EGFR:
fmol mg- I membrane protein.
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Figure 1 EGFR levels (expressed as fmol mg' of membrane
protein) found in normal a, and carcinomatous b, colorectal
tissue biopsy samples according to their intra-colonic localisation:
Caecum, AScending colon, TRansverse colon, DEScending colon,
SIGmoid and RECtum.
as when analysed as two separate groups (X2w = 4, d.f. = 1,
P.,= 0.001) (Table I and Figure 2).
No regional variation in the EGFR levels of the colorectal
carcinoma biopsy samples could be observed (Figure lb). No
association between the tumours EGFR content nor the
normal/tumour EGFR ratio and patient age, sex, tumour
stage or differentiation grade could be observed (data not
shown).
Discussion
Our data, for the first time, clearly show that measurable
amounts of EGFR are present in cell membrane preparations
from colorectal carcinomas as well as in those from the
normal colorectal mucosa. Moreover, EGFR levels were sig-
nificantly higher in normal colorectal mucosa than in the
corresponding carcinomas.
In previous studies employing EGFR ligand binding
assays, other investigators did not find statistically significant
differences in the EGFR levels between carcinomatous and
normal colorectal tissue (Yasui et al., 1988; Moorghen et al.,
1990; Rothbauer et al., 1989), although in the study by
Rothbauer et al. a trend towards higher EGFR levels in the
normal colorectal mucosa, compared to the levels in the
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Figure 2 Relation between EGFR levels (expressed as fmol
mg-' of membrane protein) found in human colorectal carcin-
oma tissue and the corresponding normal colorectal mucosa.
colorectal carcinomas was observed. We have shown (Figure
la) that the inter-individual variation of EGFR levels in the
normal colorectal mucosa has, at least in part, to be
explained by topographical variations in EGFR levels. The
use of (topographically) unpaired biopsy samples of colorec-
tal mucosa and carcinoma in the study by Yasui et al. (1988)
might therefore have obscured the difference between EGFR
levels in normal and carcinomatous tissue. Second, in our
study we exclusively isolated the colorectal mucosa by scrap-
ing it off the muscularis mucosae. Lacking information on
the method of isolation of the normal colorectal mucosa by
other groups, it is possible that the normal colorectal tissue
samples they analysed comprised not only the mucosa, the
tissue layer from which the colorectal carcinomas originate,
but also the deeper colorectal tissue layers, shown to be
devoid of EGFR (Zimmerman et al., 1988). Should this have
been the case, then they have underestimated, knowing that
the EGFR levels are expressed as fmol mg- of membrane
protein, the EGFR levels in their normal colorectal 'mucosa'
samples. Third, as ligand binding assays are apt to give a
false negative assay result if the membrane protein level falls
below a certain threshold (0.2 mg of membrane protein ml-'
when assaying breast carcinomas, Koenders et al., 1991) the
substantial amount (0.5 mg of membrane protein ml-') of
colorectal tissue cell membrane protein used in our series
contributes to the validity of our results. The use of a multiple
point EGFR assay in our series might explain the higher levels
of EGFR obtained. In the previous studies using ligand bind-
ing assays a total of 80 colorectal tissue samples, carcinoma or
normal tissue, were analysed, and in all cases the presence of
EGFR could be demonstrated (Yasui et al., 1988; Rothbauer
et al., 1989; Moorghen et al., 1990). In sharp contrast with
these observations Magnusson et al., 1989 also employing a
ligand binding assay, reported EGFR in only 25% of colorec-
tal cancers. Studies using immunohistochemical methods for
the detection of EGFR reported percentages of EGFR positi-
vity varying from 25% to 100% in colorectal carcinomas
(Ravikumar et al., 1989; Steele et al., 1990b) and from 0% to
50% in normal colorectal tissue (Ravikumar et al., 1989;
Koretz et al., 1990). Thus, except for one study, results on
the prevalence of EGFR, using ligand binding assays, are
consistent in that both colorectal carcinomas and normal
colorectal tissue contain detectable levels of EGFR, whereas
the percentages of EGFR positivity reported by groups using
immunohistochemical methods to detect EGFR are at vari-
ance with each other, but lower than those reported by
groups using ligand binding assays.
The presence of high EGFR levels in the normal colorectal
mucosa along with the observed regional differences in colo-
rectal EGFR levels suggest EGFR to be implicated in the
process of growth and differentiation of the normal colorec-
tal mucosa. The clinical implementation of EGFR and/or
EGF targeted anti-cancer drugs, might therefore be seriously
impaired, due to the anticipated growth inhibitory effects of
these drugs on the intestinal mucosa.
Our observation that EGFR is significantly lower in colo-
rectal carcinomas than in the respective normal colorectal
mucosa indicates that the original EGFR content decreases
upon malignant transformation. In contrast, Liu et al., 1990
reported that TGFa is expressed at higher levels in colorectal
carcinomas than in normal colorectal tissue, it may therefore
well be that the lower EGFR content in colorectal carcino-
mas is caused by a downregulation of the receptor by a
locally produced ligand. Therefore the tumours capability to
produce growth factors rather than the expression of the
growth factor receptor might be the factor determining its
growth capacity.
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